ABSTRACT
Capnocytophaga canimorsus is an Anaerobic Gram-Negative bacterium present in the oral microbiology of cats and dogs. It can produce infections in humans, being capable of causing severe complications with the development of septic shock. There are known cases where this bacterium developed medical complications like thrombotic microangiopathy and disseminated intravascular coagulation. We have the case of 79 years old male that developed thrombotic microangiopathy and splenic infarction linked to bacteraemia by Capnocytophaga canimorsus. Due to its severity, it was necessary to start renal replacement therapy and several sessions of plasmapheresis with good evolution. (AU)
Capnocytophaga canimorsus es una bacteria anaerobia gramnegativa presente en la microbiología oral de gatos y perros. Puede producir infecciones en humanos, siendo capaz de provocar un diagnóstico severo con desarrollo de shock séptico. Existen casos descritos con complicaciones médicas como Microangiopatía Trombótica y Coagulación Intravascular Diseminada. Presentamos el caso de un varón de 79 años que desarrolló microangiopatía trombótica e infarto esplénico asociado a bacteriemia por Capnocytophaga canimorsus. Por su gravedad, fue necesario iniciar terapia de reemplazo renal y varias sesiones de plasmaféresis con buena evolución. (AU)
Subject(s)
Humans , Male , Aged , Thrombotic Microangiopathies/diagnosis , Thrombotic Microangiopathies/surgery , Thrombotic Microangiopathies/therapy , Kidney Transplantation , Shock, Septic , Bacteremia , CapnocytophagaABSTRACT
AIM: To analyze the effects of subcutaneous or intravenous rituximab + lymphokine-activated killer cells, obinutuzumab or ibrutinib on natural killer (NK) cell levels in chronic lymphocytic leukemia and follicular lymphoma patients. PATIENTS & METHODS: The distribution of peripheral blood NK cells of 31 patients was analyzed by flow cytometry. RESULTS: We detected a decrease of NK cells in peripheral blood below normal range after obinutuzumab treatment. During maintenance treatment with subcutaneous rituximab, an NK cell reduction was less pronounced than after intravenous rituximab treatment, despite lymphokine-activated killer cell infusions. CONCLUSION: After one dose of obinutuzumab, each NK cell in peripheral blood destroys 25 leukemic cells.
